Abbott Laboratories (ABT) Projected to Post Quarterly Earnings on Thursday

Abbott Laboratories (NYSE:ABT - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Thursday, July 17th. Analysts expect Abbott Laboratories to post earnings of $1.25 per share and revenue of $11.01 billion for the quarter. Abbott Laboratories has set its Q2 2025 guidance at 1.230-1.270 EPS and its FY 2025 guidance at 5.050-5.250 EPS.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings data on Wednesday, April 16th. The healthcare product maker reported $1.09 EPS for the quarter, beating the consensus estimate of $1.07 by $0.02. Abbott Laboratories had a return on equity of 19.01% and a net margin of 31.89%. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.38 billion. On average, analysts expect Abbott Laboratories to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Abbott Laboratories Price Performance

ABT traded down $1.66 during trading on Friday, hitting $131.95. The company's stock had a trading volume of 4,661,224 shares, compared to its average volume of 6,161,139. The company has a current ratio of 1.78, a quick ratio of 1.27 and a debt-to-equity ratio of 0.26. Abbott Laboratories has a twelve month low of $99.71 and a twelve month high of $141.23. The business's fifty day simple moving average is $133.52 and its 200 day simple moving average is $129.07. The firm has a market capitalization of $229.56 billion, a price-to-earnings ratio of 17.11, a P/E/G ratio of 2.51 and a beta of 0.73.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th will be paid a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.79%. The ex-dividend date of this dividend is Tuesday, July 15th. Abbott Laboratories's dividend payout ratio is presently 30.61%.

Analyst Ratings Changes

ABT has been the topic of a number of research analyst reports. Leerink Partnrs upgraded Abbott Laboratories to a "hold" rating in a research report on Monday, June 16th. Stifel Nicolaus boosted their price objective on Abbott Laboratories from $135.00 to $145.00 and gave the company a "buy" rating in a report on Thursday, April 17th. Barclays boosted their price objective on Abbott Laboratories from $158.00 to $159.00 and gave the company an "overweight" rating in a report on Thursday, April 17th. Raymond James Financial boosted their target price on Abbott Laboratories from $132.00 to $142.00 and gave the stock an "outperform" rating in a research note on Thursday, April 17th. Finally, Piper Sandler reissued an "overweight" rating and issued a $145.00 target price (up from $133.00) on shares of Abbott Laboratories in a research report on Thursday, April 17th. Six research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $143.11.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, Director Sally E. Blount sold 2,600 shares of Abbott Laboratories stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total value of $337,116.00. Following the completion of the transaction, the director owned 34,058 shares in the company, valued at approximately $4,415,960.28. The trade was a 7.09% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.46% of the stock is owned by company insiders.

Hedge Funds Weigh In On Abbott Laboratories

An institutional investor recently raised its position in Abbott Laboratories stock. Brighton Jones LLC raised its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 10.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 51,719 shares of the healthcare product maker's stock after purchasing an additional 4,755 shares during the quarter. Brighton Jones LLC's holdings in Abbott Laboratories were worth $5,850,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 75.18% of the company's stock.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.